Inhibition of rate of tumour growth in rodent species by inoculation of herpesviruses and encephalomyocarditis virus

Cowan, M.; Davies, J.; Brookes, K.; Billstrom, Marcella A.; McLeish, P.; Buchan, A.; Skinner, G. R. B.

doi:10.1002/jmv.1890300313

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, wild-type HSV1 was shown to slow the rate of subcutaneous tumor growth in guinea pigs and mice [17], although no complete regressions were noted. More recently, a thymidine kinase-deficient (TK-) HSV1 mutant, with markedly decreased neurovirulence, was used to inhibit the growth of human gliomas in immunodeficient nude mice [18].…”

Section: Introductionmentioning

confidence: 98%

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

et al. 1994

View full text Add to dashboard Cite

Herpes simplex virus (HSV) mutants kill dividing tumor cells but spare non-proliferating, healthy brain tissue and may be useful in developing new treatment strategies for malignant brain tumors. Two HSV mutants, a thymidine kinase deficient virus (TK-) and a ribonucleotide reductase mutant (RR-), killed 7/7 human tumor cell lines in tissue culture. The TK-HSV killed Rat RG2 glioma and W256 carcinoma lines but not the rat C6 glioma in culture. TK-HSV replication (12 pfu/cell) was similar to wild-type HSV (10 pfu/cell) in rapidly dividing W256 cells in tissue culture, but was minimal (< 1 pfu/cell) in serum-starved cells, suggesting that the proliferative activity of tumor cells at the site and time of TK-HSV injection may influence efficacy in vivo. Subcutaneous W256 tumors in male Sprague-Dawley rats were injected with TK-HSV or free inoculum. A significant effect of TK-HSV therapy on W256 tumor growth was demonstrated compared to controls (p = 0.002). Complete regression was observed in 4/9 experimental tumors, with no recurrence over 6 months. Tumor growth in the remaining 5/9 animals was attenuated during the first 3 to 5 days after treatment, but not beyond 5 days compared to 9 matched control animals; no tumor regression was observed in any of the control animals. These results suggest that HSV mutants are potentially useful as novel therapeutic agents in the treatment of tumors in immunocompetent subjects.

show abstract

Section: Introductionmentioning

confidence: 98%